Celera Genomics Easily Tops Analysts' Estimates

Celera Genomics (CRA Quote) posted a narrower-than-expected loss in the latest third quarter, as revenue doubled from the same period a year ago.

The company, which analyzes and distributes genomic and medical information, lost $29.1 million, or 48 cents a share, in the quarter. According to Thomson Financial/First Call, analysts were looking for a loss of 57 cents. Celera lost $24.1 million, or 45 cents a share, in last year's third quarter. The latest quarter includes a noncash charge of $10.9 million, or 17 cents a share, primarily related to the acquisition of Paracel.

Celera's revenue for the third quarter ended March 31 rose to $23.4 million from $11.1 million in the same period a year ago. ...